Company intelligence / Profile preview

Spice Island

Rensselaer, New York, United States

Ownership: Private
Development stage: Other

Overview

Spice Island Therapeutics is a clinical-stage biotechnology company focused on developing novel anti-angiogenic and anti-cancer therapies. The company's lead candidate, Nano-diamino-tetrac (NDAT), is a nanoparticulate formulation of a thyroid hormone analogue that targets the integrin alpha-v beta-3 receptor. This receptor is overexpressed on cancer cells and tumor-associated blood vessels, allowing NDAT to inhibit tumor growth and angiogenesis while delivering targeted therapy. Spice Island Therapeutics primarily targets hard-to-treat cancers, including glioblastoma and pancreatic cancer, through its proprietary nanoparticle delivery platform.

Therapeutic areas: Oncology
Modalities: NanoparticleSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Spice Island.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spice Island.

Explore the full profile